OCTA and Polypoidal Choroidal Vasculopathy

Federico II University

Status

Completed

Conditions

Polypoidal Choroidal Vasculopathy

Treatments

Drug: Ranibizumab Injection

Study type

Observational

Funder types

Other

Identifiers

NCT04714242

1401/21

Details and patient eligibility

About

To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.

Full description

Polypoidal choroidal vasculopathy represents a distinct form of choroidal neovascularization.

The study investigated the changes in choroidal vascular network after anti-VEGF therapy using optical coherence tomography angiography, a novel and non invasive diagnostic technique that allows to better understand the pathophysiologic mechanism of this neovascularization.

Enrollment

60 patients

Sex

All

Ages

60 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

age older than 60 years
diagnosis of polypoidal choroidal vasculopathy
absence of previous ocular surgery, congenital eye disease, high myopia (>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases.
absence of significant lens opacities, low-quality OCT-A images.

Exclusion criteria

age older than 80 years
absence of diagnosis of polypoidal choroidal vasculopathy
presence of previous ocular surgery, congenital eye disease, high myopia (>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases.
presence of significant lens opacities, low-quality OCT-A images.